1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Macular Edema in 3 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Macular Edema: Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response." | 8.12 | Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022) |
| "This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response." | 4.12 | Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Muto, T | 1 |
| Machida, S | 1 |
| Ahmadieh, H | 2 |
| Nourinia, R | 2 |
| Hafezi-Moghadam, A | 2 |
| Sabbaghi, H | 1 |
| Nakao, S | 1 |
| Zandi, S | 1 |
| Yaseri, M | 1 |
| Tofighi, Z | 1 |
| Akbarian, S | 1 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Macular Edema
| Article | Year |
|---|---|
Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Di | 2019 |
2 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Macular Edema
| Article | Year |
|---|---|
Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Diabetes Mellitus; Diabetic Retinopathy; Humans | 2022 |
Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal | 2013 |